
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics Inc. is poised for a positive trajectory, driven by increasing confidence in the efficacy of its clinical-stage gene therapy candidates TN-201 and TN-401, with success probabilities adjusted upward to 30% and 15%, respectively. The presentation of promising preclinical data for TN-301, highlighting significant improvements in muscle strength and reduced biomarkers of muscle damage, further bolsters the company's potential in treating rare genetic disorders. Additionally, encouraging safety profiles and clinically meaningful improvements in patients receiving TN-401 indicate a strong foundation for future developments and regulatory alignments anticipated in 2026.
Bears say
The analysis highlights significant concerns regarding Tenaya Therapeutics Inc., primarily due to the potential delays in transitioning preclinical assets to the clinical stage, which could adversely affect market sentiment and prompt downward revisions to financial estimates. Additionally, the company's ability to scale manufacturing capacity poses a risk to meeting forecasts, further complicating its financial outlook. Furthermore, emerging safety signals related to immune reactions during clinical trials could negatively impact both investor confidence and the company's valuation.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares